EpicentRx Presents Poster on the Nephroprotective Effects of RRx-001 in Patients with Solid Tumors that Receive Cisplatin/Etoposide at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

On February 15, 2023 EpicentRx, Inc. ("EpicentRx"), a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, reported that it has been selected for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO) (Free ASCO Whitepaper) being held February 16-18 in San Francisco (Press release, EpicentRx, FEB 15, 2023, View Source [SID1234627257]).The poster presents evidence of nephroprotective effects for RRx-001 in a 90 patient trial called QUADRUPLE THREAT where patients received cisplatin/etoposide + RRx-001 as treatment for small cell lung cancer (SCLC), high grade neuroendocrine cancers, HGNEC, non-small cell lung cancer (NSCLC), and ovarian cancer (OC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the company’s poster presentation are below:

Abstract Title: Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors.

Session Title: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Abstract Number for Publication: 657

Session Date and Time: Saturday, February 18, 2023: 12:30 PM – 2 PM

About RRx-001
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. RRx-001 is under investigation in a Phase 3 trial for the treatment of small cell lung cancer (SCLC), and in a Phase 2 trial for protection against oral mucositis in first line head and neck cancer. It is also under development as a medical countermeasure for nuclear and radiological emergencies and as a treatment for neurodegenerative diseases like Parkinson’s and ALS/MND.